+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stimulation of Eryptosis by Afatinib



Stimulation of Eryptosis by Afatinib



Cellular Physiology and Biochemistry 47(3): 1259-1273



The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is primarily utilized for the treatment of non-small cell lung carcinoma. The drug is at least partially effective by triggering suicidal tumor cell death. Side effects of afatinib treatment include anemia. At least in theory, afatinib induced anemia could be secondary to stimulation of suicidal erythrocyte death or eryptosis, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Signaling potentially stimulating eryptosis include increase of cytosolic Ca2+ activity ([Ca2+]i), induction of oxidative stress, and increase of ceramide abundance. The present study explored, whether afatinib induces eryptosis and, if so, whether its effect involves Ca2+ entry, oxidative stress, and/or ceramide. Flow cytometry was employed to quantify phosphatidylserine exposure at the cell surface from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, reactive oxygen species (ROS) abundance from DCFDA dependent fluorescence, and ceramide abundance utilizing specific antibodies. A 48 hours exposure of human erythrocytes to afatinib (≥ 4 µg/ml) significantly increased the percentage of annexin-V-binding cells and significantly decreased forward scatter. Afatinib significantly increased Fluo3-fluorescence, DCFDA fluorescence and ceramide abundance. The effect of afatinib on annexin-V-binding and forward scatter was significantly blunted by removal of extracellular Ca2+. Afatinib triggers phospholipid scrambling of the erythrocyte cell membrane, an effect at least in part due to Ca2+ entry, oxidative stress, and ceramide.

(PDF emailed within 0-6 h: $19.90)

Accession: 065534813

Download citation: RISBibTeXText

PMID: 29913444

DOI: 10.1159/000490221


Related references

Stimulation of Eryptosis by Caspofungin. Cellular Physiology and Biochemistry 39(3): 939-949, 2016

Stimulation of Eryptosis by Narasin. Cellular Physiology and Biochemistry 37(5): 1807-1816, 2016

Stimulation of eryptosis by cryptotanshinone. Cellular Physiology and Biochemistry 34(2): 432-442, 2015

Stimulation of eryptosis by anti-A IgG antibodies. Cellular Physiology and Biochemistry 20(5): 591-600, 2007

Stimulation of eryptosis by aluminium ions. Toxicology and Applied Pharmacology 217(2): 168-175, 2006

Stimulation of eryptosis by cadmium ions. Cellular Physiology and Biochemistry 22(1-4): 245-252, 2008

Sulindac sulfide--induced stimulation of eryptosis. Cellular Physiology and Biochemistry 30(4): 1072-1082, 2013

Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P). Cellular Physiology and Biochemistry 38(3): 969-981, 2016

Stimulation of Eryptosis, the Suicidal Erythrocyte Death by Piceatannol. Cellular Physiology and Biochemistry 38(6): 2300-2310, 2016

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E). International Journal of Radiation Oncology*biology*physics 90(5): S39-S40, 2014

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment 49(4): 1001-1011, 2017

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Clinical Cancer Research 22(2): 426-435, 2016

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer 113: 51-58, 2017

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 27(3): 417-423, 2015

OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial. Journal of Thoracic Oncology 12(1): S334-S335, 2017